Trial Profile
Phase II study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, who have a Drug Response Predictor (DRP) indicating a high likelihood of response to Irofulven
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Irofulven (Primary) ; Prednisolone
- Indications Adenocarcinoma; Carcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Allarity Therapeutics; Oncology Venture
- 19 Jul 2023 Planned End Date changed from 1 May 2023 to 1 May 2024.
- 14 Apr 2023 This trial has been completed in Denmark (Date of the global end of the trial: 06-Jan-2023), according to the European Clinical Trials Database record.
- 09 Mar 2023 According to Lantern Pharma Media Release, status changed to discontinued to allow the focus of LP-100-directed resources on positioning the molecule for development in earlier lines of therapy with potentially larger market opportunities